Therapeutic targeting of tumor suppressor genes
Cet article passe en revue les différentes méthodes susceptibles d'être mises en oeuvre pour développer des traitements attaquant les tumeurs dans lesquelles des gènes suppresseurs de tumeurs sont inactivés
Carcinogenesis is a multistep process attributable to both gain-of-function mutations in oncogenes and loss-of-function mutations in tumor suppressor genes. Currently, most molecular targeted therapies are inhibitors of oncogenes, because inactivated tumor suppressor genes have proven harder to “drug.” Nevertheless, in cancers, tumor suppressor genes undergo alteration more frequently than do oncogenes. In recent years, several promising strategies directed at tumor suppressor genes, or the pathways controlled by these genes, have emerged. Here, we describe advances in a number of different methodologies aimed at therapeutically targeting tumors driven by inactivated tumor suppressor genes.